Reyedar at EUNOS 2026 in Milan
At EUNOS 2026 in Milan, Reyedar presented results from clinical studies and pilots in spinocerebellar ataxia, acquired brain injury, paediatric neuro-ophthalmology and glaucoma.
This week, Reyedar is at EUNOS 2026 in Milan, presenting results from clinical trials and pilots in four areas: ataxia, acquired brain injury, paediatric neuro-ophthalmology and glaucoma. New biomarkers, methodologies and insights, all derived from our proprietary eye-tracking platform.
The four posters and the work behind them:
- Spinocerebellar ataxia type 3: de Boer et al. (2025), Frontiers in Neurology.
- Acquired brain injury: Vrijling et al. (2025), Acta Ophthalmologica.
- Paediatric neuro-ophthalmology: Bøthun et al., in review.
- Glaucoma: Vrijling et al. (2025), Translational Vision Science & Technology, and the screening study, in review.
The published papers are on our Publications page, and the Digital biomarker page explains the method behind them. You can also download the four posters (PDF, 9 MB).
Research: applications other than glaucoma are under investigation and are not part of SONDA’s cleared clinical use. SONDA is CE-marked as an aid in the diagnosis and staging of primary open-angle glaucoma.
